Anti-atrial Fibrillatory and Cardiorenal Protective Effects of the Combination of Valsartan and Cilnidipine in Dahl Salt-Sensitive Rats
Biological and Pharmaceutical Bulletin · 2024
DOI: 10.1248/bpb.b24-00265 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2024. Verfasst von Eri Harada und 2 weiteren Autor:innen. Beteiligte Einrichtung: EA Pharma Co., Ltd. (Formerly Ajinomoto Pharmaceuticals Co., Ltd.). Hauptthemen laut MEDLINE: Valsartan, Rats, Inbred Dahl, Dihydropyridines, Calcium Channel Blockers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
The current study aimed to investigate the anti-atrial fibrillatory (AF) effects of a combination of valsartan and a calcium channel blocker (cilnidipine or amlodipine) in Dahl salt-sensitive (Dahl S) rats. Seven-week-old male Dahl S rats were fed an 8% salt diet. Six weeks later, valsartan (60 mg/kg, Val group), cilnidipine + valsartan (10 + 60 mg/kg, CV group), amlodipine + valsartan (3 + 60 mg/kg, AV group), or vehicle was orally administered daily for 5 weeks. Echocardiography and atrial electrophysiological evaluations were performed on the last day of treatment. Blood pressure in each drug treatment group was lower than in the Vehicle group. The duration of AF induced by atrial burst stimulation was shorter in the Val group (3.2 ± 1.6 s) than in the Vehicle group (11.2 ± 6.0 s), which was further shortened in the CV and AV groups (1.1 ± 0.3 and 1.3 ± 0.3 s, respectively). Left ventricular ejection fraction and left ventricular fractional shortening were greater in the CV and AV groups than those in the Vehicle group. Urinary albumin excretion in the CV group was the lowest among the drug-treated groups. The results collectively suggest that the combination of a calcium channel blocker with valsartan could be useful in terms of its anti-AF action as well as for improving cardiac and renal functions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- EA Pharma Co., Ltd. (Formerly Ajinomoto Pharmaceuticals Co., Ltd.).
- Ajinomoto Co., Inc.
- Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Toho University.
Zitieren
APA
Harada, E., Sugino, K., & Takahara, A. (2024). Anti-atrial Fibrillatory and Cardiorenal Protective Effects of the Combination of Valsartan and Cilnidipine in Dahl Salt-Sensitive Rats. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b24-00265
Vancouver
Harada E, Sugino K, Takahara A. Anti-atrial Fibrillatory and Cardiorenal Protective Effects of the Combination of Valsartan and Cilnidipine in Dahl Salt-Sensitive Rats. Biological and Pharmaceutical Bulletin. 2024. doi:10.1248/bpb.b24-00265
BibTeX
@article{Harada2024,
author = {Harada, Eri and Sugino, Kazumi and Takahara, Akira},
title = {Anti-atrial Fibrillatory and Cardiorenal Protective Effects of the Combination of Valsartan and Cilnidipine in Dahl Salt-Sensitive Rats},
journal = {Biological and Pharmaceutical Bulletin},
year = {2024},
doi = {10.1248/bpb.b24-00265}
}
EUVIMED